Penggunaan Seftriakson Vs Penisilin Pada Pasien Leptospirosis Berat: Tinjauan Naratif

Nanang Munif Yasin; Dwi Pujilestari; Titik Nuryastuti

doi:10.22146/farmaseutik.v19i3.80477

Penggunaan Seftriakson Vs Penisilin Pada Pasien Leptospirosis Berat: Tinjauan Naratif

https://doi.org/10.22146/farmaseutik.v19i3.80477

Nanang Munif Yasin^(1*), Dwi Pujilestari⁽²⁾, Titik Nuryastuti⁽³⁾

(1) Faculty of Pharmacy UGM
(2) Magister Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(3) Fakultas Kedokteran, Kesehatan Masyarakat, dan Keperawatan, Universitas Gadjah Mada
(*) Corresponding Author

Abstract

Leptospirosis penyakit demam septik akut yang disebabkan bakteri leptospira interrogan. leptospirosis merupakan salah satu penyebab zoonosis terpenting morbiditas dan mortilitas. Tatalaksana leptospirosis dengan menggunakan panduan yang diatur oleh Kemenkes pada tahun 2017. Antibiotik yang digunakan yakni penisilin atau seftriakson. Studi ini bertujuan untuk mengetahui efektivitas penggunaan antibiotik seftriakson di bandingkan penisilin dengan metode tinjauan naratif menggunakan artikel dari database Cochrane, Pubmed, dan Scopus. Pencarian artikel menggunakan kata kunci, leptospirosis, Weil’s syndrom, penisilin dan Seftriakson, case study, cohort dan Randomized Control Trial (RCT), yang terbit antara tahun 2012 hingga 2022. Hasil penyaringan didapatkan 8 artikel studi yang masuk kriteria inklusi dan eksklusi. Efektivitas antibiotik seftriakson lebih baik dari penisilin. Dengan luaran klinik pasien membaik. Kesimpulan pada studi tinjauan naratif ini, terapi leptospirosis selama rawat inap disesuaikan dengan kondisi klinik pasien. seftriakson dan penisilin merupakan antibiotik yang aman digunakan pada pasien leptospirosis. Penggunaan seftriakson lebih efektif digunakan sebagai pilihan terapi pada leptospirosis berat.

Keywords

Leptospirosis; Ceftriaxone; Penicillin

Full Text:

PDF

References

Leptospirosis, CDC. Published March 13, 2019. Accessed August 26, 2021. https://www.cdc.gov/leptospirosis/index.html

De Brito T, Silva AMG da, Abreu PAE. Pathology and pathogenesis of human leptospirosis: a commented review. Rev Inst Med Trop São Paulo. 2018;60(0). doi:10.1590/s1678-9946201860023

Costa F, Hagan JE, Calcagno J, et al. Global Morbidity and Mortality of Leptospirosis: A Systematic Review. Small PLC, ed. PLoS Negl Trop Dis. 2015;9(9):e0003898. doi:10.1371/journal.pntd.0003898

Haake DA, Levett PN. Leptospirosis in Humans. In: Adler B, ed. Leptospira and Leptospirosis. Vol 387. Current Topics in Microbiology and Immunology. Springer Berlin Heidelberg; 2015:65-97. doi:10.1007/978-3-662-45059-8_5

Schönfeld A, Jensen B, Orth HM, Tappe D, Feldt T, Häussinger D. Severe pulmonary haemorrhage syndrome in leptospirosis in a returning traveller. Infection. 2019;47(1):125-128. doi:10.1007/s15010-018-1220-7

Ceftriaxone - an overview | ScienceDirect Topics. Published 2014. Accessed November 23, 2022. https://www.sciencedirect.com/topics/medicine-and-dentistry/ceftriaxone

PubChem Compound. Summary for CID 23679441, CID 23679441. https://pubchem.ncbi.nlm.nih.gov/compound/23679441. Published 2022. Accessed October 1, 2022. https://pubchem.ncbi.nlm.nih.gov/compound/23679441

Faucher JF, Chirouze C, Hoen B, Leroy J, Hustache-Mathieu L, Estavoyer JM. Short-course treatment with ceftriaxone for leptospirosis: A retrospective study in a single center in Eastern France. J Infect Chemother. 2015;21(3):227-228. doi:10.1016/j.jiac.2014.09.002

Rawls SM. Antibiotics, β-Lactam. In: Aminoff MJ, Daroff RB, eds. Encyclopedia of the Neurological Sciences (Second Edition). Academic Press; 2014:207-209.

doi:10.1016/B978-0-12-385157-4.00250-5

Zeng L, Wang C, Jiang M, et al. Safety of ceftriaxone in paediatrics: a systematic review. Arch Dis Child. 2020;105(10):981-985. doi:10.1136/archdischild-2019-317950

Ressner RA, Griffith ME, Beckius ML, et al. Antimicrobial Susceptibilities of Geographically Diverse Clinical Human Isolates of Leptospira. Antimicrob Agents Chemother. 2008;52(8):2750-2754. doi:10.1128/AAC.00044-08

Guzmán Pérez M, Blanch Sancho JJ, Segura Luque JC, Mateos Rodriguez F, Martínez Alfaro E, Solís García del Pozo J. Current Evidence on the Antimicrobial Treatment and Chemoprophylaxis of Human Leptospirosis: A Meta-Analysis. Pathogens. 2021;10(9):1125. doi:10.3390/pathogens10091125

Raptis L, Pappas G, Akritidis N. Use of ceftriaxone in patients with severe leptospirosis. Int J Antimicrob Agents. 2006;28(3):259-261. doi:10.1016/j.ijantimicag.2006.04.011

Hospenthal DR, Murray CK. In Vitro Susceptibilities of Seven Leptospira Species to Traditional and Newer Antibiotics. Antimicrob Agents Chemother. 2003;47(8):2646-2648.

doi:10.1128/AAC.47.8.2646-2648.2003

Suzuki R, Terayama M, Tanda M. Severe leptospirosis infection in a non-epidemic area. IDCases. 2021;26:e01345. doi:10.1016/j.idcr.2021.e01345

Faggion Vinholo T, Ribeiro GS, Silva NF, et al. Severe leptospirosis after rat bite: A case report. Caimano MJ, ed. PLoS Negl Trop Dis. 2020;14(7):e0008257. doi:10.1371/journal.pntd.0008257

Kang YM, Hagiwara A, Uemura T. Leptospirosis infection in a homeless patient in December in Tokyo: a case report. J Med Case Reports. 2015;9(1):198. doi:10.1186/s13256-015-0687-4

Rozalena S, Handayani L, Arman A, Permata M, Hudari H. Weil’s disease in a 36 years old female: a case report. IOP Conf Ser Earth Environ Sci. 2018;125:012066. doi:10.1088/1755-1315/125/1/012066

Sarkar J, Chopra A, Katageri B, Raj H, Goel A. Leptospirosis: a re-emerging infection. Asian Pac J Trop Med. 2012;5(6):500-502. doi:10.1016/S1995-7645(12)60086-8

Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman’s the Pharmacological Basis of Therapeutics.; 2018.

Penicillin G - ClinicalKey. Accessed October 13, 2022. https://www-clinicalkey-com.ezproxy.ugm.ac.id/#!/content/drug_monograph/6-s2.0-470

Selvarajah S, Ran S, Roberts NW, Nair M. Leptospirosis in pregnancy: A systematic review. Casanovas-Massana A, ed. PLoS Negl Trop Dis. 2021;15(9):e0009747. doi:10.1371/journal.pntd.0009747

Schlossberg D, Samuel R. Antibiotics Manual: A Guide to Commonly Used Antimicrobials. John Wiley & Sons, Ltd; 2017. doi:10.1002/9781119220787

Fisher JF, Mobashery S. Constructing and deconstructing the bacterial cell wall. Protein Sci Publ Protein Soc. 2020;29(3):629-646. doi:10.1002/pro.3737

Yip DW, Gerriets V. Penicillin. In: StatPearls. StatPearls Publishing; 2022. Accessed October 18, 2022. http://www.ncbi.nlm.nih.gov/books/NBK554560/

Trevor AJ, Trevor, Kruidering-Hall M, Katzung BG. Katzung & Trevor’s Pharmacology: Examination & Board Review.; 2015.

Puliyath G, Singh S. Leptospirosis in pregnancy. Eur J Clin Microbiol Infect Dis. 2012;31(10):2491-2496. doi:10.1007/s10096-012-1625-7

Panaphut T, Domrongkitchaiporn S, Vibhagool A, Thinkamrop B, Susaengrat W. Ceftriaxone Compared with Sodium Penicillin G for Treatment of Severe Leptospirosis. Clin Infect Dis. 2003;36(12):1507-1513. doi:10.1086/375226

Wysocki J, Liu Y, Shores N. Leptospirosis with Acute Liver Injury. Bayl Univ Med Cent Proc. 2014;27(3):257-258. doi:10.1080/08998280.2014.11929130

Daher EF, Silva GB, de Abreu KLS, et al. Leptospirosis-associated acute kidney injury: penicillin at the late stage is still controversial: Penicillin in leptospirosis. J Clin Pharm Ther. 2012;37(4):420-425. doi:10.1111/j.1365-2710.2011.01312.x

Aygün FD, Avar-Aydın PÖ, Çokuğraş H, Camcıoğlu Y. Different clinical spectrum of leptospirosis. Turk J Pediatr. 2016;58(2):212. doi:10.24953/turkjped.2016.02.015

DOI: https://doi.org/10.22146/farmaseutik.v19i3.80477